JP2023527937A5 - - Google Patents
Info
- Publication number
- JP2023527937A5 JP2023527937A5 JP2023515227A JP2023515227A JP2023527937A5 JP 2023527937 A5 JP2023527937 A5 JP 2023527937A5 JP 2023515227 A JP2023515227 A JP 2023515227A JP 2023515227 A JP2023515227 A JP 2023515227A JP 2023527937 A5 JP2023527937 A5 JP 2023527937A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020092092 | 2020-05-25 | ||
| CNPCT/CN2020/092092 | 2020-05-25 | ||
| PCT/CN2021/095411 WO2021238831A1 (en) | 2020-05-25 | 2021-05-24 | Anti-cldn18.2 antibodies and diagnostic uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527937A JP2023527937A (ja) | 2023-06-30 |
| JP2023527937A5 true JP2023527937A5 (https=) | 2024-05-31 |
Family
ID=78745623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515227A Pending JP2023527937A (ja) | 2020-05-25 | 2021-05-24 | 抗ｃｌｄｎ１８．２抗体及びその診断用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230331836A1 (https=) |
| EP (1) | EP4157885A4 (https=) |
| JP (1) | JP2023527937A (https=) |
| KR (1) | KR20230016212A (https=) |
| CN (1) | CN115836090A (https=) |
| AU (1) | AU2021279777A1 (https=) |
| CA (1) | CA3184008A1 (https=) |
| MX (1) | MX2022014896A (https=) |
| TW (1) | TWI878541B (https=) |
| WO (1) | WO2021238831A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117295524A (zh) | 2021-06-02 | 2023-12-26 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
| CN114539410B (zh) * | 2022-03-15 | 2023-09-05 | 苏州量化细胞生物科技有限公司 | Cldn18.2结合抗体、探针及在cldn18.2表达细胞的单细胞测序中的应用 |
| WO2023196882A1 (en) * | 2022-04-06 | 2023-10-12 | Zai Lab (Us) Llc | Claudin 18.2 immunohistochemistry assay and use thereof |
| CN114428174B (zh) * | 2022-04-07 | 2022-07-08 | 北京肿瘤医院(北京大学肿瘤医院) | 一种胃癌预后生物标志物及其应用 |
| WO2024199673A1 (en) * | 2023-03-31 | 2024-10-03 | Università Degli Studi Di Verona | Methods for predicting and improving therapeutic efficacy of cancer treatments and methods for cancer prognosis |
| WO2024211459A1 (en) * | 2023-04-04 | 2024-10-10 | Zai Lab (Shanghai) Co., Ltd | Use of anti-claudin antibody for cancer treatment based on certain biomarkers |
| CN121399468A (zh) * | 2023-05-08 | 2026-01-23 | 安捷伦科技有限公司 | 诊断和治疗癌症的免疫组织化学（ihc）方案和方法 - 密封蛋白18.2 |
| EP4720132A1 (en) * | 2023-06-03 | 2026-04-08 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving claudin 18.2 antagonists for treatment of cancer |
| KR20260028757A (ko) * | 2023-06-08 | 2026-03-04 | 안텐진 바이올로직스 리미티드 | 항-cldn18.2 항체 및 이의 진단적 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US10858415B2 (en) * | 2014-01-29 | 2020-12-08 | Tron—Translationale Onkologie An Der Universitatsmedizin Der Johannes Guttenberg-Universitat Mainz Gemeinnuizige Gmbh | Peptide mimotopes of claudin 18.2 and uses thereof |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| US11059887B2 (en) * | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN110606891B (zh) * | 2018-06-17 | 2022-12-06 | 上海健信生物医药科技有限公司 | 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途 |
| KR20210050547A (ko) * | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
| EP3872093A4 (en) * | 2018-10-22 | 2022-10-19 | Shanghai Genbase Biotechnology Co., Ltd. | ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
-
2021
- 2021-05-24 WO PCT/CN2021/095411 patent/WO2021238831A1/en not_active Ceased
- 2021-05-24 MX MX2022014896A patent/MX2022014896A/es unknown
- 2021-05-24 JP JP2023515227A patent/JP2023527937A/ja active Pending
- 2021-05-24 US US17/927,740 patent/US20230331836A1/en active Pending
- 2021-05-24 AU AU2021279777A patent/AU2021279777A1/en active Pending
- 2021-05-24 TW TW110118625A patent/TWI878541B/zh active
- 2021-05-24 EP EP21812540.9A patent/EP4157885A4/en active Pending
- 2021-05-24 CA CA3184008A patent/CA3184008A1/en active Pending
- 2021-05-24 KR KR1020227045389A patent/KR20230016212A/ko active Pending
- 2021-05-24 CN CN202180041601.5A patent/CN115836090A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527937A5 (https=) | ||
| CN102971343B (zh) | 用于癌症诊断和/或预后的新型抗体 | |
| JP6239503B2 (ja) | 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用 | |
| JP2018042573A5 (https=) | ||
| JP6138780B2 (ja) | 癌の検出および診断のための抗体ｉ−３８５９の使用 | |
| JP2020530272A5 (https=) | ||
| WO2010033913A1 (en) | Antibodies, analogs and uses thereof | |
| AU2015265976A1 (en) | Anti-B7-H3 antibodies and diagnostic uses thereof | |
| JP2020534830A5 (https=) | ||
| JP6129956B2 (ja) | 抗ｃ−Ｍｅｔ抗体 | |
| JP6947435B2 (ja) | 炭酸脱水素酵素に結合する抗体およびその用途 | |
| JP6940505B2 (ja) | 組成物および癌の発生リスクの評価方法 | |
| AU2022222311A1 (en) | Vegfa-binding molecules | |
| WO2018135653A1 (ja) | 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出 | |
| JP2023508023A (ja) | Ｃｘｃｌ１０結合タンパク質及びその使用 | |
| CN121219584A (zh) | 针对nr1的自身抗体的检测 | |
| CN114761803B (zh) | 使用抗bag2抗体诊断癌症的方法 | |
| CN120535623B (zh) | Cdh17结合分子及其用途 | |
| CN115210256A (zh) | 用于前列腺癌诊断的新方法和化合物 | |
| CN120535630B (zh) | 一种靶向cdh17的大羊驼纳米抗体、结合分子及其应用 | |
| FI131968B1 (en) | ANTIBODY BINDINGS AS CANCER BIOMARKERS | |
| KR102172541B1 (ko) | Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법 | |
| US20190194319A1 (en) | Anti-ascl1 antibodies and methods of use | |
| KR20110091476A (ko) | 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물 | |
| WO2018213680A1 (en) | Diagnostic antibodies and methods of use |